Natural products continue to be an important source of leads for new medicines, despite reduced interest from large pharmaceutical companies.
Screening collections of natural products can be assembled economically to provide excellent coverage of drug-like chemical space and in formats that are compatible with high-throughput bioassays.
Metabolomics enables the rapid identification of novel compounds in complex mixtures of natural products and also provides a means to monitor the production of target molecules during fermentation or other production processes.
Metagenomics and other genetic engineering techniques are enabling the production of target compounds in convenient systems, breaking away from the bottleneck otherwise created by microorganisms that are difficult to culture.
Examples of recent and current applications of natural products are described for the discovery of antimicrobials and for inhibitors of protein–protein interactions, particularly as anticancer agents.
Natural products have been a rich source of compounds for drug discovery. However, their use has diminished in the past two decades, in part because of technical barriers to screening natural products in high-throughput assays against molecular targets. Here, we review strategies for natural product screening that harness the recent technical advances that have reduced these barriers. We also assess the use of genomic and metabolomic approaches to augment traditional methods of studying natural products, and highlight recent examples of natural products in antimicrobial drug discovery and as inhibitors of protein–protein interactions. The growing appreciation of functional assays and phenotypic screens may further contribute to a revival of interest in natural products for drug discovery.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Harvey, A. L. Natural products in drug discovery. Drug Discov. Today 13, 894–901 (2008).
Harvey, A. L. & Gericke, N. in Biodiversity Ch. 15 (ed. Pavlinov, I. Y.) 323–338 (Intech, 2011).
Dias, D. A., Urban, S. & Roessner, U. A historical overview of natural products in drug discovery. Metabolites 2, 303–333 (2012).
Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 75, 311–335 (2012). This is a detailed examination of the origins of the new medicines approved by the FDA.
Mishra, B. B. & Tiwari, V. K. Natural products: an evolving role in future drug discovery. Eur. J. Med. Chem. 46, 4769–4807 (2011).
Carter, G. T. Natural products and pharma 2011: strategic changes spur new opportunities. Nat. Prod. Rep. 28, 1783–1789 (2011).
Cragg, G. M. & Newman, D. J. Natural products: a continuing source of novel drug leads. Biochim. Biophys. Acta 1830, 3670–3695 (2013).
Butler, M. S., Blaskovich, M. A. & Cooper, M. A. Antibiotics in the clinical pipeline in 2013. J. Antibiot. 66, 571–591 (2013).
Rishton, G. M. Natural products as a robust source of new drugs and drug leads: past successes and present day issues. Am J. Cardiol. 101, 43D–49D (2008).
Drewry, D. H. & Macarron, R. Enhancements of screening collections to address areas of unmet medical need: an industry perspective. Curr. Opin. Chem. Biol. 14, 289–298 (2010).
Sukuru, S. C. et al. Plate-based diversity selection based on empirical HTS data to enhance the number of hits and their chemical diversity. J. Biomol. Screen 14, 690–699 (2009).
Macarron, R. et al. Impact of high-throughput screening in biomedical research. Nature Rev. Drug Discov. 10, 188–195 (2011).
Wetzel, S., Bon, R. S., Kumar, K. & Waldmann, H. Biology-oriented synthesis. Angew. Chem. Int. Ed. 50, 10800–10826 (2011). This is a review of how structural information from natural products can be used to create screening libraries of biologically relevant compounds.
Lachance, H., Wetzel, S., Kumar, K. & Waldmann, H. Charting, navigating, and populating natural product chemical space for drug discovery. J. Med. Chem. 55, 5989–6001 (2012).
Grabowski, K., Baringhaus, K. H. & Schneider, G. Scaffold diversity of natural products: inspiration for combinatorial library design. Nat. Prod. Rep. 25, 892–904 (2008).
Rosén, J., Gottfries, J., Muresan, S., Backlund, A. & Oprea, T. I. Novel chemical space exploration via natural products. J. Med. Chem. 52, 1953–1962 (2009).
Bauer, R. A., Wurst, J. M. & Tan, D. S. Expanding the range of 'druggable' targets with natural product-based libraries: an academic perspective. Curr. Opin. Chem. Biol. 14, 308–314 (2010).
Hert, J., Irwin, J. J., Laggner, C., Keiser, M. J. & Shoichet, B. K. Quantifying biogeninc bias in screening libraries. Nature Chem. Biol. 5, 479–483 (2009).
Schenone, M., Dancik, V., Wagner, B. K. & Clemons, P. A. Target identification and mechanism of action in chemical biology and drug discovery. Nature Chem. Biol. 9, 232–240 (2013).
Eggert, U. S. The why and how of phenotypic small-molecule screens. Nature Chem. Biol. 9, 206–209 (2013).
Zhao, L. et al. Targeting the human genome-microbiome axis for drug discovery: inspirations from global systems biology and traditional Chinese medicine. J. Proteome Res. 11, 3509–3519 (2012).
Barlow, D. J. et al. In-silico studies in Chinese herbal medicines' research: evaluation of in-silico methodologies and phytochemical data sources, and a review of research to date. J. Ethnopharmacol. 140, 526–534 (2012).
May, B. H., Lu, C. & Xue, C. C. Collections of traditional Chinese medical literature as resources for systematic searches. J. Altern. Complement Med. 18, 1101–1107 (2012).
Gyllenhaal, C. et al. Ethnobotanical approach versus random approach in the search for new bioactive compounds: support of a hypothesis. Pharm. Biol. 50, 30–41 (2012).
Quinn, R. J. in Chemical Genomics (ed. Fu, H.) 87–98 (Cambridge Univ. Press, 2012).
Wall, M. E. et al. Effect of tannins on screening of plant extracts for enzyme inhibitory activity and techniques for their removal. Phytomedicine 3, 281–285 (1996).
Eldridge, G. R. et al. High-throughput method for the production and analysis of large natural product libraries for drug discovery. Anal. Chem. 74, 3963–3971 (2002).
Appleton, D. R., Buss, A. D. & Butler, M. S. A simple method for high-throughput extract prefractionation for biological screening. Chimia 61, 327–331 (2007).
Wagenaar, M. M. Pre-fractionated microbial samples — the second generation natural products library at Wyeth. Molecules 13, 1406–1426 (2008).
Bugni, T. S. et al. Marine natural product libraries for high-throughput screening and rapid drug discovery. J. Nat. Prod. 71, 1095–1098 (2008).
Tu, Y. et al. Automated high-throughput system to fractionate plant natural products for drug discovery. J. Nat. Prod. 73, 751–754 (2010).
Kato, N., Takahashi, S., Nogawa, T., Saito, T. & Osada, H. Construction of a microbial natural product library for chemical biology studies. Curr. Opin. Chem. Biol. 16, 101–108 (2012).
Camp, D., Davis, R. A., Campitelli, M., Ebdon, J. & Quinn, R. J. Drug-like properties: guiding principles for the design of natural product libraries. J. Nat. Prod. 75, 72–81 (2012). This is a description of how screening collections can be prepared from natural-product extracts that are enriched with compounds that have physicochemical properties typical of drugs.
Ymele-Leki, P. et al. A high-throughput screen identifies a new natural product with broad-spectrum antibacterial activity. PLoS ONE 7, e31307 (2012).
Hashimoto, J. et al. Novel in vitro protein fragment complementation assay applicable to high-throughput screening in a 1536-well format. J. Biomolecular Screen. 14, 970–979 (2009).
Wong, W. R., Oliver, A. G. & Linington, R. G. Development of antibiotic activity profile screening for the classification and discovery of natural product antibiotics. Chem. Biol. 19, 1483–1495 (2012).
Wess, G., Urmann, M. & Sickenberger, B. Medicinal chemistry: challenges and opportunities. Angew. Chem. Int. Ed. 40, 3341–3350 (2001).
Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3–25 (1997).
Oprea, T. I. Property distribution of drug-related chemical databases. J. Comput. Aided Mol. Design 14, 251–264 (2000).
McArdle, B. M., Campitelli, M. R. & Quinn, R. J. A common protein fold topology shared by flavonoid biosynthetic enzymes and therapeutic targets. J. Nat. Prod. 69, 14–17 (2006).
Kellenberger, E., Hofmann, A. & Quinn, R. J. Similar interactions of natural products with biosynthetic enzymes and therapeutic targets could explain why nature produces such a large proportion of existing drugs. Nat. Prod. Rep. 28, 1483–1492 (2011).
Quinn, R. J. et al. Developing a drug-like natural product library. J. Nat. Prod. 71, 464–468 (2008).
Henkel, T., Brunne, R., Muller, H. & Reichel, F. Statistical investigation of structural complementarity of natural products and synthetic compounds. Angew. Chem. Int. Ed. 38, 643–647 (1999).
Feher, M. & Schmidt, J. M. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inform. Computer Sci. 43, 218–227 (2003). This is a detailed exploration of the coverage of chemical space by compounds from different classes, showing the close match between drugs and natural products.
Pascolutti, M. & Quinn, R. J. Natural products as lead-structures; chemical transformations to create lead-like libraries. Drug Discov. Today 19, 215–221 (2013).
Teague, S. J., Davis, A. M., Leeson, P. D. & Oprea, T. The design of leadlike combinatorial libraries. Angew. Chem. Int. Ed. 38, 3743–3748 (1999).
Keserü, G. M. & Makara, G. M. The influence of lead discovery strategies on the properties of drug candidates. Nature Rev. Drug Discov. 8, 203–212 (2009).
Khersonsky, S. M. & Chang, Y. -T. Forward chemical genetics: library scaffold design. Comb. Chem. High Throughput Screen. 7, 645–652 (2004).
Clark, R. L. et al. The Drug Discovery Portal: a resource to enhance drug discovery from academia. Drug Discov. Today 15, 679–683 (2010).
Hur, M. et al. A global approach to analysis and interpretation of metabolic data for plant natural product discovery. Nat. Prod. Rep. 30, 565–583 (2013).
Craig, J. W., Chang, F. Y., Kim, J. H., Obiajulu, S. C. & Brady, S. F. Expanding small-molecule functional metagenomics through parallel screening of broad-host-range cosmid environmental DNA libraries in diverse proteobacteria. Appl. Environ. Microbiol. 76, 1633–1641 (2010).
Kersten, R. D. et al. A mass spectrometry-guided genome mining approach for natural product peptidogenomics. Nature Chem. Biol. 7, 794–802 (2011).
Schlotterbeck, G., Ross, A., Dieterle, F. & Senn, H. Metabolic profiling technologies for biomarker discovery in biomedicine and drug development. Pharmacogenomics 7, 1055–1075 (2006).
Harrigan, G. Metabolic profiling: pathways in drug discovery. Drug Discov. Today 7, 351–352 (2002).
Fraser, P. D., Pinto, M. E., Holloway, D. E. & Bramley, P. M. Technical advance: application of high-performance liquid chromatography with photodiode array detection to the metabolic profiling of plant isoprenoids. Plant J. 24, 551–558 (2000).
Macintyre, L. et al. Metabolomic tools for secondary metabolite discovery from marine microbial symbionts. Mar. Drugs 12, 3416–3448 (2014).
Glassbrook, N., Beecher, C. & Ryals, J. Metabolic profiling on the right path. Nature Biotech. 18, 1142–1143 (2000). This paper demonstrates the connection between gene expression and metabolite production through high-throughput techniques for monitoring various cell functions and detecting small molecules and proteins.
Viegelmann, C. et al. Metabolomic profiling and genomic study of a marine sponge-associated streptomyces sp. Mar. Drugs 12, 3323–3351 (2014).
Bochner, B. R. Global phenotypic characterization of bacteria. FEMS Microbiol. Rev. 33, 191–205 (2009).
Jewett, M. C., Hofmann, G. & Nielsen, J. Fungal metabolite analysis in genomics and phenomics. Curr. Opin. Biotechnol. 17, 191–197 (2006). This paper demonstrates how metabolomics can play an essential role in functional genomics and strain classification.
Ohta, D., Kanaya, S. & Suzuki, H. Application of Fourier-transform ion cyclotron resonance mass spectrometry to metabolic profiling and metabolite identification. Curr. Opin. Biotechnol. 21, 35–44 (2010).
Hufsky, F., Scheubert, K. & Bocker, S. New kids on the block: novel informatics methods for natural product discovery. Nat. Prod. Rep. 31, 807–817 (2014).
Pauli, G. F. et al. Essential parameters for structural analysis and dereplication by 1H NMR spectroscopy. J. Nat. Prod. 77, 1473–1487 (2014).
Halabalaki, M., Vougogiannopoulou, K., Mikros, E. & Skaltsounis, A. L. Recent advances and new strategies in the NMR-based identification of natural products. Curr. Opin. Biotechnol. 25, 1–7 (2014).
Hubert, J. et al. Identification of natural metabolites in mixture: a pattern recognition strategy based on 13C NMR. Anal. Chem. 86, 2955–2962 (2014).
Grkovic, T. et al. NMR fingerprints of the drug-like natural-product space identify iotrochotazine A: a chemical probe to study Parkinson's disease. Angew. Chem. Int. Ed Engl. 53, 6070–6074 (2014).
Tawfike, A. F., Viegelmann, C. & Edrada-Ebel, R. Metabolomics and dereplication strategies in natural products. Methods Mol. Biol. 1055, 227–244 (2013).
Abdelmohsen, U. R. et al. Dereplication strategies for targeted isolation of new antitrypanosomal actinosporins A and B from a marine sponge associated-Actinokineospora sp. EG49. Mar. Drugs 12, 1220–1244 (2014).
Ebada, S. S., Edrada, R. A., Lin, W. & Proksch, P. Methods for isolation, purification and structural elucidation of bioactive secondary metabolites from marine invertebrates. Nature Protoc. 3, 1820–1831 (2008).
Kjer, J., Debbab, A., Aly, A. H. & Proksch, P. Methods for isolation of marine-derived endophytic fungi and their bioactive secondary products. Nature Protoc. 5, 479–490 (2010).
Yilmaz, A., Nyberg, N. T. & Jaroszewski, J. W. Metabolic profiling based on two-dimensional J-resolved 1H NMR data and parallel factor analysis. Anal. Chem. 83, 8278–8285 (2011).
Gray, A. I., Igoli, J. O. & Edrada-Ebel, R. Natural products isolation in modern drug discovery programs. Methods Mol. Biol. 864, 515–534 (2012).
Yuliana, N. D., Khatib, A., Choi, Y. H. & Verpoorte, R. Metabolomics for bioactivity assessment of natural products. Phytother Res. 25, 157–169 (2011).
Eugster, P. J., Glauser, G. & Wolfender, J. L. Strategies in biomarker discovery. Peak annotation by MS and targeted LC-MS micro-fractionation for de novo structure identification by micro-NMR. Methods Mol. Biol. 1055, 267–289 (2013).
Palomino-Schatzlein, M., Molina-Navarro, M. M., Tormos-Perez, M., Rodriguez-Navarro, S. & Pineda-Lucena, A. Optimised protocols for the metabolic profiling of S. cerevisiae by H-NMR and HRMAS spectroscopy. Anal. Bioanal. Chem. 405, 8431–8441 (2013).
Johansen, K. T., Wubshet, S. G. & Nyberg, N. T. HPLC-NMR revisited: using time-slice high-performance liquid chromatography-solid-phase extraction-nuclear magnetic resonance with database-assisted dereplication. Anal. Chem. 85, 3183–3189 (2013).
Barding, G. A. Jr., Orr, D. J., Sathnur, S. M. & Larive, C. K. VIZR–an automated chemometric technique for metabolic profiling. Anal. Bioanal. Chem. 405, 8409–8417 (2013).
Ibrahim, A. et al. Dereplicating nonribosomal peptides using an informatic search algorithm for natural products (iSNAP) discovery. Proc. Natl Acad. Sci. USA 109, 19196–19201 (2012).
Pluskal, T., Castillo, S., Villar-Briones, A. & Oresic, M. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics 11, 395 (2010).
Katajamaa, M., Miettinen, J. & Oresic, M. MZmine: toolbox for processing and visualization of mass spectrometry based molecular profile data. Bioinformatics 22, 634–636 (2006).
Pluskal, T., Uehara, T. & Yanagida, M. Highly accurate chemical formula prediction tool utilizing high-resolution mass spectra, MS/MS fragmentation, heuristic rules, and isotope pattern matching. Anal. Chem. 84, 4396–4403 (2012).
Tautenhahn, R., Patti, G. J., Rinehart, D. & Siuzdak, G. X.C.M. S. Online: a web-based platform to process untargeted metabolomic data. Anal. Chem. 84, 5035–5039 (2012).
Smith, C. A., Want, E. J., O'Maille, G., Abagyan, R. & Siuzdak, G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 78, 779–787 (2006).
Yuliana, N. D., Khatib, A., Verpoorte, R. & Choi, Y. H. Comprehensive extraction method integrated with NMR metabolomics: a new bioactivity screening method for plants, adenosine A1 receptor binding compounds in Orthosiphon stamineus Benth. Anal. Chem. 83, 6902–6906 (2011).
Fukuda, S. et al. Evaluation and characterization of bacterial metabolic dynamics with a novel profiling technique, real-time metabolotyping. PLoS ONE 4, e4893 (2009).
Rateb, M. E. et al. Diverse metabolic profiles of a Streptomyces strain isolated from a hyper-arid environment. J. Nat. Prod. 74, 1965–1971 (2011).
Bills, G. F. et al. Enhancement of antibiotic and secondary metabolite detection from filamentous fungi by growth on nutritional arrays. J. Appl. Microbiol. 104, 1644–1658 (2008).
Zhu, F. et al. The main byproducts and metabolic flux profiling of gamma-PGA-producing strain B. subtilis ZJU-7 under different pH values. J. Biotechnol. 164, 67–74 (2013).
Jorda, J. et al. Metabolic flux profiling of recombinant protein secreting Pichia pastoris growing on glucose: methanol mixtures. Microb. Cell Fact. 11, 57 (2012).
Toya, Y. & Shimizu, H. Flux analysis and metabolomics for systematic metabolic engineering of microorganisms. Biotechnol. Adv. 31, 818–826 (2013).
Wang, M. et al. Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology. Phytother Res. 19, 173–182 (2005).
Youns, M., Hoheisel, J. D. & Efferth, T. Toxicogenomics for the prediction of toxicity related to herbs from traditional Chinese medicine. Planta Med. 76, 2019–2025 (2010).
Yu, J., Nag, S. A. & Zhang, R. Advances in translational pharmacological investigations in identifying and validating molecular targets of natural product anticancer agents. Curr. Cancer Drug Targets 13, 596–609 (2013).
Pelkonen, O. et al. Omics and its potential impact on R&D and regulation of complex herbal products. J. Ethnopharmacol. 140, 587–593 (2012).
Zheng, L. et al. A chemometric study of chromatograms of tea extracts by correlation optimization warping in conjunction with PCA, support vector machines and random forest data modeling. Anal. Chim. Acta 642, 257–265 (2009).
Zhao, J. et al. Chemometric resolution of coeluting peaks of eleven antihypertensives from multiple classes in high performance liquid chromatography: a comprehensive research in human serum, health product and Chinese patent medicine samples. J. Chromatogr. B 902, 96–107 (2012).
Inui, T., Wang, Y., Pro, S. M., Franzblau, S. G. & Pauli, G. F. Unbiased evaluation of bioactive secondary metabolites in complex matrices. Fitoterapia 83, 1218–1225 (2012).
Li, Y., Wang, Y., Su, L., Li, L. & Zhang, Y. Exploring potential chemical markers by metabolomics method for studying the processing mechanism of traditional Chinese medicine using RPLC-Q-TOF/MS: a case study of Radix Aconiti. Chem. Cent. J. 7, 36 (2013).
Sun, H. et al. UPLC-Q-TOF-HDMS analysis of constituents in the root of two kinds of Aconitum using a metabolomics approach. Phytochem. Anal. 24, 263–276 (2013).
Mao, Q. et al. Target separation of a new anti-tumor saponin and metabolic profiling of leaves of Panax notoginseng by liquid chromatography with eletrospray ionization quadrupole time-of-flight mass spectrometry. J. Pharm. Biomed. Anal. 59, 67–77 (2012).
Krizevski, R. et al. Benzaldehyde is a precursor of phenylpropylamino alkaloids as revealed by targeted metabolic profiling and comparative biochemical analyses in Ephedra spp. Phytochemistry 81, 71–79 (2012).
Cheng, Q. et al. Effects of combined elicitors on tanshinone metabolic profiling and SmCPS expression in Salvia miltiorrhiza hairy root cultures. Molecules 18, 7473–7485 (2013).
Wang, X. et al. Differential cardioprotective effects of salvianolic acid and tanshinone on acute myocardial infarction are mediated by unique signaling pathways. J. Ethnopharmacol. 135, 662–671 (2011).
Buenafe, O. E. et al. Tanshinone IIA exhibits anticonvulsant activity in zebrafish and mouse seizure models. ACS Chem. Neurosci. 4, 1479–1487 (2013).
Wilson, M. C. & Piel, J. Metagenomic approaches for exploiting uncultivated bacteria as a resource for novel biosynthetic enzymology. Chem. Biol. 20, 636–647 (2013).
Abe, T. et al. Construction of a metagenomic library for the marine sponge Halichondria okadai. Biosci. Biotechnol. Biochem. 76, 633–639 (2012).
Piel, J. Approaches to capturing and designing biologically active small molecules produced by uncultured microbes. Annu. Rev. Microbiol. 65, 431–453 (2011).
Donia, M. S., Ruffner, D. E., Cao, S. & Schmidt, E. W. Accessing the hidden majority of marine natural products through metagenomics. Chembiochem 12, 1230–1236 (2011). This paper describes a metagenomic method to discover cyanobacterial natural products, and provides a proof of concept for genome-based discovery of marine natural products.
Donia, M. S. & Schmidt, E. W. Linking chemistry and genetics in the growing cyanobactin natural products family. Chem. Biol. 18, 508–519 (2011).
Gurgui, C. & Piel, J. Metagenomic approaches to identify and isolate bioactive natural products from microbiota of marine sponges. Methods Mol. Biol. 668, 247–264 (2010).
Duan, C. J. & Feng, J. X. Mining metagenomes for novel cellulase genes. Biotechnol. Lett. 32, 1765–1775 (2010).
Ouyang, Y. et al. Isolation of high molecular weight DNA from marine sponge bacteria for BAC library construction. Mar. Biotechnol. 12, 318–325 (2010).
Rodriguez, E., Menzella, H. G. & Gramajo, H. Heterologous production of polyketides in bacteria. Methods Enzymol. 459, 339–365 (2009).
Kennedy, J., Marchesi, J. R. & Dobson, A. D. Metagenomic approaches to exploit the biotechnological potential of the microbial consortia of marine sponges. Appl. Microbiol. Biotechnol. 75, 11–20 (2007).
Gerwick, W. H. & Moore, B. S. Lessons from the past and charting the future of marine natural products drug discovery and chemical biology. Chem. Biol. 19, 85–98 (2012).
Udwary, D. W. et al. Significant natural product biosynthetic potential of actinorhizal symbionts of the genus frankia, as revealed by comparative genomic and proteomic analyses. Appl. Environ. Microbiol. 77, 3617–3625 (2011).
Pereyra, L. P., Hiibel, S. R., Prieto Riquelme, M. V., Reardon, K. F. & Pruden, A. Detection and quantification of functional genes of cellulose- degrading, fermentative, and sulfate-reducing bacteria and methanogenic archaea. Appl. Environ. Microbiol. 76, 2192–2202 (2010).
Bull, A. T., Ward, A. C. & Goodfellow, M. Search and discovery strategies for biotechnology: the paradigm shift. Microbiol. Mol. Biol. Rev. 64, 573–606 (2000). This is a review of strategies to integrate biotechnology with molecular biology and the discovery of novel bioactive natural products from uncultivated microorganisms.
Khodadad, C. L. & Foster, J. S. Metagenomic and metabolic profiling of nonlithifying and lithifying stromatolitic mats of Highborne Cay, The Bahamas. PLoS ONE 7, e38229 (2012).
Kurtboke, D. I. Biodiscovery from rare actinomycetes: an eco-taxonomical perspective. Appl. Microbiol. Biotechnol. 93, 1843–1852 (2012).
Wu, J., Gao, W., Zhang, W. & Meldrum, D. R. Optimization of whole-transcriptome amplification from low cell density deep-sea microbial samples for metatranscriptomic analysis. J. Microbiol. Methods 84, 88–93 (2011).
Lefevre, F. et al. Drugs from hidden bugs: their discovery via untapped resources. Res. Microbiol. 159, 153–161 (2008).
Ongley, S. E., Bian, X., Neilan, B. A. & Muller, R. Recent advances in the heterologous expression of microbial natural product biosynthetic pathways. Nat. Prod. Rep. 30, 1121–1138 (2013).
Cruz-Morales, P. et al. The genome sequence of Streptomyces lividans 66 reveals a novel tRNA-dependent peptide biosynthetic system within a metal-related genomic island. Genome Biol. Evol. 5, 1165–1175 (2013).
Lim, F. Y., Sanchez, J. F., Wang, C. C. & Keller, N. P. Toward awakening cryptic secondary metabolite gene clusters in filamentous fungi. Methods Enzymol. 517, 303–324 (2012).
Gomez-Escribano, J. P. & Bibb, M. J. Streptomyces coelicolor as an expression host for heterologous gene clusters. Methods Enzymol. 517, 279–300 (2012).
Nguyen, Q. T. et al. Metabolomics methods for the synthetic biology of secondary metabolism. FEBS Lett. 586, 2177–2183 (2012).
Bian, X., Plaza, A., Zhang, Y. & Muller, R. Luminmycins A-C, cryptic natural products from Photorhabdus luminescens identified by heterologous expression in Escherichia coli. J. Nat. Prod. 75, 1652–1655 (2012).
Bergmann, S. et al. Activation of a silent fungal polyketide biosynthesis pathway through regulatory cross talk with a cryptic nonribosomal peptide synthetase gene cluster. Appl. Environ. Microbiol. 76, 8143–8149 (2010).
Baltz, R. H. Streptomyces and Saccharopolyspora hosts for heterologous expression of secondary metabolite gene clusters. J. Ind. Microbiol. Biotechnol. 37, 759–772 (2010).
Stevens, D. C. et al. Alternative sigma factor over-expression enables heterologous expression of a type II polyketide biosynthetic pathway in Escherichia coli. PLoS ONE 8, e64858 (2013).
Jiang, M., Zhang, H. & Pfeifer, B. A. The logic, experimental steps, and potential of heterologous natural product biosynthesis featuring the complex antibiotic erythromycin A produced through E. coli. J. Vis. Exp. e4346 (2013).
Cimini, D., De Rosa, M., Carlino, E., Ruggiero, A. & Schiraldi, C. Homologous overexpression of RfaH in E. coli K4 improves the production of chondroitin-like capsular polysaccharide. Microb. Cell Fact. 12, 46 (2013).
Malla, S., Koffas, M. A., Kazlauskas, R. J. & Kim, B. G. Production of 7-O-methyl aromadendrin, a medicinally valuable flavonoid, in Escherichia coli. Appl. Environ. Microbiol. 78, 684–694 (2012).
Boghigian, B. A., Zhang, H. & Pfeifer, B. A. Multi-factorial engineering of heterologous polyketide production in Escherichia coli reveals complex pathway interactions. Biotechnol. Bioeng. 108, 1360–1371 (2011).
Lemuth, K., Steuer, K. & Albermann, C. Engineering of a plasmid-free Escherichia coli strain for improved in vivo biosynthesis of astaxanthin. Microb. Cell Fact. 10, 29 (2011).
Kwon, S. K., Park, Y. K. & Kim, J. F. Genome-wide screening and identification of factors affecting the biosynthesis of prodigiosin by Hahella chejuensis, using Escherichia coli as a surrogate host. Appl. Environ. Microbiol. 76, 1661–1668 (2010).
Morrone, D. et al. Increasing diterpene yield with a modular metabolic engineering system in E. coli: comparison of MEV and MEP isoprenoid precursor pathway engineering. Appl. Microbiol. Biotechnol. 85, 1893–1906 (2010).
Liu, H. et al. Rapid cloning and heterologous expression of the meridamycin biosynthetic gene cluster using a versatile Escherichia coli-streptomyces artificial chromosome vector, pSBAC. J. Nat. Prod. 72, 389–395 (2009).
Yan, Y., Huang, L. & Koffas, M. A. Biosynthesis of 5-deoxyflavanones in microorganisms. Biotechnol. J. 2, 1250–1262 (2007).
Hwang, E. I., Kaneko, M., Ohnishi, Y. & Horinouchi, S. Production of plant-specific flavanones by Escherichia coli containing an artificial gene cluster. Appl. Environ. Microbiol. 69, 2699–2706 (2003).
Carlsen, S. et al. Heterologous expression and characterization of bacterial 2-C-methyl-d-erythritol- 4-phosphate pathway in Saccharomyces cerevisiae. Appl. Microbiol. Biotechnol. 97, 5753–5769 (2013).
Shao, Z. & Zhao, H. DNA assembler: a synthetic biology tool for characterizing and engineering natural product gene clusters. Methods Enzymol. 517, 203–224 (2012).
Naesby, M. et al. Yeast artificial chromosomes employed for random assembly of biosynthetic pathways and production of diverse compounds in Saccharomyces cerevisiae. Microb. Cell Fact 8, 45 (2009).
Oliver, S. G. From genomes to systems: the path with yeast. Phil. Trans. R. Soc. B 361, 477–482 (2006). The paper describes the integration of flux balance analysis with genetics and metabolomics to define a metabolic system.
Chemler, J. A., Yan, Y. & Koffas, M. A. Biosynthesis of isoprenoids, polyunsaturated fatty acids and flavonoids in Saccharomyces cerevisiae. Microb. Cell Fact. 5, 20 (2006).
Mutka, S. C., Bondi, S. M., Carney, J. R., Da Silva, N. A. & Kealey, J. T. Metabolic pathway engineering for complex polyketide biosynthesis in Saccharomyces cerevisiae. FEMS Yeast Res. 6, 40–47 (2006).
Jones, A. C. et al. Evaluation of Streptomyces coelicolor A3(2) as a heterologous expression host for the cyanobacterial protein kinase C activator lyngbyatoxin A. FEBS J. 279, 1243–1251 (2012).
Shao, Z. et al. Refactoring the silent spectinabilin gene cluster using a plug-and-play scaffold. ACS Synth. Biol. 2, 662–669 (2013).
Kersten, R. D. et al. Bioactivity-guided genome mining reveals the lomaiviticin biosynthetic gene cluster in Salinispora tropica. Chembiochem 14, 955–962 (2013).
Chen, Q. et al. Discovery of McbB, an enzyme catalyzing the β-carboline skeleton construction in the marinacarboline biosynthetic pathway. Angew. Chem. Int. Ed Engl. 52, 9980–9984 (2013).
Nikolouli, K. & Mossialos, D. Bioactive compounds synthesized by non-ribosomal peptide synthetases and type-I polyketide synthases discovered through genome-mining and metagenomics. Biotechnol. Lett. 34, 1393–1403 (2012).
Brakhage, A. A. et al. Activation of fungal silent gene clusters: a new avenue to drug discovery. Prog. Drug Res. 66, 3–12 (2008).
Sandiford, S. K. Advances in the arsenal of tools available enabling the discovery of novel lantibiotics with therapeutic potential. Expert Opin. Drug Discov. 9, 283–297 (2014).
Chen, L. et al. Genomics-driven discovery of the pneumocandin biosynthetic gene cluster in the fungus Glarea lozoyensis. BMC Genomics 14, 339 (2013).
Nakazawa, T. et al. Overexpressing transcriptional regulator in Aspergillus oryzae activates a silent biosynthetic pathway to produce a novel polyketide. Chembiochem 13, 855–861 (2012).
Berthier, E. et al. Low-volume toolbox for the discovery of immunosuppressive fungal secondary metabolites. PLoS Pathog. 9, e1003289 (2013).
Brierley, I. Macrolide-induced ribosomal frameshifting: a new route to antibiotic resistance. Mol. Cell 52, 613–615 (2013).
Harfe, B. D. & Jinks-Robertson, S. Removal of frameshift intermediates by mismatch repair proteins in Saccharomyces cerevisiae. Mol. Cell. Biol. 19, 4766–4773 (1999).
Moldenhauer, J., Chen, X. H., Borriss, R. & Piel, J. Biosynthesis of the antibiotic bacillaene, the product of a giant polyketide synthase complex of the trans-AT family. Angew. Chem. Int. Ed Engl. 46, 8195–8197 (2007).
Nah, J. H. et al. Identification and biotechnological application of novel regulatory genes involved in Streptomyces polyketide overproduction through reverse engineering strategy. Biomed. Res. Int. 2013, 549737 (2013).
Gerth, K., Bedorf, N., Hofle, G., Irschik, H. & Reichenbach, H. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (myxobacteria). Production, physico-chemical and biological properties. J. Antibiot. 49, 560–563 (1996).
He, H. et al. Lomaiviticins A and B, potent antitumor antibiotics from Micromonospora lomaivitiensis. J. Am. Chem. Soc. 123, 5362–5363 (2001).
Narvi, E. et al. Altered TUBB3 expression contributes to the epothilone response of mitotic cells. Br. J. Cancer 108, 82–90 (2013).
Alvarez, R. H., Valero, V. & Hortobagyi, G. N. Ixabepilonefor the treatment of breast cancer. Ann. Med. 43, 477–486 (2011).
Molnar, I. et al. The biosynthetic gene cluster for the microtubule-stabilizing agents epothilones A and B from Sorangium cellulosum So ce90. Chem. Biol. 7, 97–109 (2000).
Julien, B. et al. Isolation and characterization of the epothilone biosynthetic gene cluster from Sorangium cellulosum. Gene 249, 153–160 (2000).
Osswald, C. et al. Modular construction of a functional artificial epothilone polyketide pathway. ACS Synth. Biol. 3, 759–772 (2012).
Waldman, A. J. & Balskus, E. P. Lomaiviticin biosynthesis employs a new strategy for starter unit generation. Org. Lett. 16, 640–643 (2014).
Jean, M., Tomasi, S. & van de Weghe, P. When the nine-membered enediynes play hide and seek. Org. Biomol. Chem. 10, 7453–7456 (2012).
Iwatsuki, M. et al. Guadinomines, type III secretion system inhibitors, produced by Streptomyces sp. K01-0509. II: physico-chemical properties and structure elucidation. J. Antibiot. 61, 230–236 (2008).
Salmond, G. P. & Reeves, P. J. Membrane traffic wardens and protein secretion in gram-negative bacteria. Trends Biochem. Sci. 18, 7–12 (1993).
Kalaitzis, J. A. Discovery, biosynthesis, and rational engineering of novel enterocin and wailupemycin polyketide analogues. Methods Mol. Biol. 1055, 171–189 (2013).
Wang, Y., Chen, S. & Yu, O. Metabolic engineering of flavonoids in plants and microorganisms. Appl. Microbiol. Biotechnol. 91, 949–956 (2011).
Lange, B. M. & Ahkami, A. Metabolic engineering of plant monoterpenes, sesquiterpenes and diterpenes — current status and future opportunities. Plant Biotechnol. J. 11, 169–196 (2013).
Liu, R., Hu, Y., Li, J. & Lin, Z. Production of soybean isoflavone genistein in non-legume plants via genetically modified secondary metabolism pathway. Metab. Eng. 9, 1–7 (2007).
van Herpen, T. W. et al. Nicotiana benthamiana as a production platform for artemisinin precursors. PLoS ONE 5, e14222 (2010).
Ro, D. K. et al. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature 440, 940–943 (2006).
Paddon, C. J. et al. High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 496, 528–532 (2013).
Paddon, C. J. & Keasling, J. D. Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development. Nature Rev. Microbiol. 12, 355–367 (2014).
Roth, R. J. & Acton, N. A simple conversion of artemisinic acid into artemisinin. J. Nat. Prod. 52, 1183–1185 (1989).
Haznagy, A. & Glusin, W. I. Isolation of naringenin from Cynachum vincetoxicum (L.) Pers. 10. Pharmazie 29, 209–210 (1974).
Leonard, E., Lim, K. H., Saw, P. N. & Koffas, M. A. Engineering central metabolic pathways for high-level flavonoid production in Escherichia coli. Appl. Environ. Microbiol. 73, 3877–3886 (2007).
Fisch, K. M. et al. Polyketide assembly lines of uncultivated sponge symbionts from structure-based gene targeting. Nature Chem. Biol. 5, 494–501 (2009).
Bayer, K., Scheuermayer, M., Fieseler, L. & Hentschel, U. Genomic mining for novel FADH2-dependent halogenases in marine sponge-associated microbial consortia. Mar. Biotechnol. 15, 63–72 (2013).
Pimentel-Elardo, S. M., Grozdanov, L., Proksch, S. & Hentschel, U. Diversity of nonribosomal peptide synthetase genes in the microbial metagenomes of marine sponges. Mar. Drugs 10, 1192–1202 (2012).
Peng, J. et al. Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections. J. Med. Chem. 53, 61–76 (2010).
Schmidt, E. W., Sudek, S. & Haygood, M. G. Genetic evidence supports secondary metabolic diversity in Prochloron spp., the cyanobacterial symbiont of a tropical ascidian. J. Nat. Prod. 67, 1341–1345 (2004).
Freeman, M. F. et al. Metagenome mining reveals polytheonamides as posttranslationally modified ribosomal peptides. Science 338, 387–390 (2012).
Wilson, M. C. et al. An environmental bacterial taxon with a large and distinct metabolic repertoire. Nature 506, 58–62 (2014).
Calcul, L., Zhang, B., Jinwal, U. K., Dickey, C. A. & Baker, B. J. Natural products as a rich source of tau-targeting drugs for Alzheimer's disease. Future Med. Chem. 4, 1751–1761 (2012).
Kim, L. C., Song, L. & Haura, E. B. Src kinases as therapeutic targets for cancer. Nature Rev. Clin. Oncol. 6, 587–595 (2009).
Zhu, L. et al. Reduction of synaptojanin 1 accelerates Abeta clearance and attenuates cognitive deterioration in an Alzheimer mouse model. J. Biol. Chem. 288, 32050–32063 (2013).
Ji, H. Y. et al. Evaluation of DA-9801, a new herbal drug for diabetic neuropathy, on metabolism-mediated interaction. Arch. Pharm. Res. 36, 1–5 (2013).
Roemer, T. & Krysan, D. J. Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb. Perspect. Med. 4, a019703 (2014).
Levy, S. B. & Marshall, B. Antibacterial resistance worldwide: causes, challenges and responses. Nature Med. 10, S122–S129 (2004).
Hawkey, P. M. The growing burden of antimicrobial resistance. J. Antimicrob. Chemother. 62 (Suppl. 1), i1–i9 (2008).
Hogberg, L. D., Heddini, A. & Cars, O. The global need for effective antibiotics: challenges and recent advances. Trends Pharmacol. Sci. 31, 509–515 (2010).
MacGowan, A. & Albur, M. Frontline antibiotic therapy. Clin. Med. 13, 263–268 (2013).
Boucher, H. W. et al. 10 x '20 Progress — development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin. Infect. Dis. 56, 1685–1694 (2013).
Chan, P. F., Macarron, R., Payne, D. J., Zalacain, M. & Holmes, D. J. Novel antibacterials: a genomics approach to drug discovery. Curr. Drug Targets Infect. Disord. 2, 291–308 (2002).
Gwynn, M. N., Portnoy, A., Rittenhouse, S. F. & Payne, D. J. Challenges of antibacterial discovery revisited. Ann. NY Acad. Sci. 1213, 5–19 (2010).
Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Rev. Drug Discov. 6, 29–40 (2007). This is a comprehensive review examining the challenges of finding new antibiotics.
Silver, L. L. Challenges of antibacterial discovery. Clin. Microbiol. Rev. 24, 71–109 (2011).
Roemer, T. & Boone, C. Systems-level antimicrobial drug and drug synergy discovery. Nature Chem. Biol. 9, 222–231 (2013).
Lewis, K. Platforms for antibiotic discovery. Nature Rev. Drug Discov. 12, 371–387 (2013).
Cushnie, T. P. & Lamb, A. J. Recent advances in understanding the antibacterial properties of flavonoids. Int. J. Antimicrob. Agents 38, 99–107 (2011).
Liu, X. et al. Systematics-guided bioprospecting for bioactive microbial natural products. Antonie Van Leeuwenhoek 101, 55–66 (2012).
Abreu, A. C., McBain, A. J. & Simoes, M. Plants as sources of new antimicrobials and resistance-modifying agents. Nat. Prod. Rep. 29, 1007–1021 (2012).
Savoia, D. Plant-derived antimicrobial compounds: alternatives to antibiotics. Future Microbiol. 7, 979–990 (2012).
Wink, M. Medicinal plants: a source of anti-parasitic secondary metabolites. Molecules 17, 12771–12791 (2012).
Radulovic, N. S., Blagojevic, P. D., Stojanovic-Radic, Z. Z. & Stojanovic, N. M. Antimicrobial plant metabolites: structural diversity and mechanism of action. Curr. Med. Chem. 20, 932–952 (2013).
Xiao, Y. et al. Antifungal screening of endophytic fungi from Ginkgo biloba for discovery of potent anti-phytopathogenic fungicides. FEMS Microbiol. Lett. 339, 130–136 (2013).
Bhatnagar, I. & Kim, S. K. Pharmacologically prospective antibiotic agents and their sources: a marine microbial perspective. Environ. Toxicol. Pharmacol. 34, 631–643 (2012).
Wang, J. et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441, 358–361 (2006).
Martens, E. & Demain, A. L. Platensimycin and platencin: promising antibiotics for future application in human medicine. J. Antibiot. 64, 705–710 (2011).
Stokes, N. R. et al. Novel inhibitors of bacterial cytokinesis identified by a cell-based antibiotic screening assay. J. Biol. Chem. 280, 39709–39715 (2005).
Baba, T. et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. Biol. 2, 2006.0008 (2006).
Chaudhuri, R. R. et al. Comprehensive identification of essential Staphylococcus aureus genes using Transposon-Mediated Differential Hybridisation (TMDH). BMC Genomics 10, 291 (2009).
Smith, A. M., Ammar, R., Nislow, C. & Giaever, G. A survey of yeast genomic assays for drug and target discovery. Pharmacol. Ther. 127, 156–164 (2010). This review examines yeast chemical genomic assays and summarizes the potential applications of each approach in identifying drug target candidates and genes involved in drug target pathways, and also defines the general cellular response to small molecules.
Ho, C. H. et al. Combining functional genomics and chemical biology to identify targets of bioactive compounds. Curr. Opin. Chem. Biol. 15, 66–78 (2011).
Brotz-Oesterhelt, H. et al. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nature Med. 11, 1082–1087 (2005).
Roemer, T. et al. Confronting the challenges of natural product-based antifungal discovery. Chem. Biol. 18, 148–164 (2011). This is a review of the difficulties in finding successful antifungal drugs and the role that natural products can have in the discovery process.
Jiang, B. et al. PAP inhibitor with in vivo efficacy identified by Candida albicans genetic profiling of natural products. Chem. Biol. 15, 363–374 (2008).
Wallace, I. M. et al. Compound prioritization methods increase rates of chemical probe discovery in model organisms. Chem. Biol. 18, 1273–1283 (2011).
Ewbank, J. J. & Zugasti, O. C. elegans: model host and tool for antimicrobial drug discovery. Dis. Model. Mech. 4, 300–304 (2011).
Benard, E. L. et al. Infection of zebrafish embryos with intracellular bacterial pathogens. J. Vis. Exp. 61, e3781 (2012).
Veneman, W. J. et al. A zebrafish high throughput screening system used for Staphylococcus epidermidis infection marker discovery. BMC Genomics 14, 255 (2013).
Moy, T. I. et al. High-throughput screen for novel antimicrobials using a whole animal infection model. ACS Chem. Biol. 4, 527–533 (2009).
Arkin, M. R. & Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nature Rev. Drug Discov. 3, 301–317 (2004).
Wells, J. A. & McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450, 1001–1009 (2007).
Smith, M. C. & Gestwicki, J. E. Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity. Expert Rev. Mol. Med. 14, e16 (2012).
Higueruelo, A. P., Jubb, H. & Blundell, T. L. Protein-protein interactions as druggable targets: recent technological advances. Curr. Opin. Pharmacol. 13, 791–796 (2013).
Thiel, P. et al. Virtual screening and experimental validation reveal novel small-molecule inhibitors of 14-3-3 protein-protein interactions. Chem. Commun. 49, 8468–8470 (2013).
Arkin, M. R. & Whitty, A. The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions. Curr. Opin. Chem. Biol. 13, 284–290 (2009).
Thiel, P., Kaiser, M. & Ottmann, C. Small-molecule stabilization of protein–protein interactions: an underestimated concept in drug discovery? Angew. Chem. Int. Ed Engl. 51, 2012–2018 (2012).
Basse, M. J. et al. 2P2Idb: a structural database dedicated to orthosteric modulation of protein-protein interactions. Nucleic Acids Res. 41, D824–827 (2013).
Higueruelo, A. P., Jubb, H. & Blundell, T. L. TIMBAL v2: update of a database holding small molecules modulating protein-protein interactions. Database 2013, bat039 (2013).
Murray, J. K. & Gellman, S. H. Targeting protein-protein interactions: lessons from p53/MDM2. Biopolymers 88, 657–686 (2007).
Domling, A. Small molecular weight protein-protein interaction antagonists: an insurmountable challenge? Curr. Opin. Chem. Biol. 12, 281–291 (2008).
Stoll, R. et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 40, 336–344 (2001).
Duncan, S. J. et al. Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J. Am. Chem. Soc. 123, 554–560 (2001).
Clark, R. C., Lee, S. Y., Searcey, M. & Boger, D. L. The isolation, total synthesis and structure elucidation of chlorofusin, a natural product inhibitor of the p53-mDM2 protein-protein interaction. Nat. Prod. Rep. 26, 465–477 (2009).
Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848 (2004).
Khoo, K. H., Verma, C. S. & Lane, D. P. Drugging the p53 pathway: understanding the route to clinical efficacy. Nature Rev. Drug Discov. 13, 217–236 (2014).
Tabernero, J. et al. A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin. Cancer Res. 17, 6313–6321 (2011).
Jones, R. J. et al. The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1. J. Pharmacol. Exp. Ther. 346, 381–392 (2013).
Reindl, W., Yuan, J., Kramer, A., Strebhardt, K. & Berg, T. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem. Biol. 15, 459–466 (2008).
Heeres, J. T. & Hergenrother, P. J. High-throughput screening for modulators of protein-protein interactions: use of photonic crystal biosensors and complementary technologies. Chem. Soc. Rev. 40, 4398–4410 (2011).
Ishi, K. & Sugawara, F. A facile method to screen inhibitors of protein-protein interactions including MDM2-p53 displayed on T7 phage. Biochem. Pharmacol. 75, 1743–1750 (2008).
Hedvat, M. et al. Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules. Anticancer Agents Med. Chem. 12, 1143–1155 (2012).
Wei, J. et al. Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J. Med. Chem. 53, 8000–8011 (2010).
Schelman, W. R. et al. A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Invest. New Drugs 32, 295–302 (2013).
Balakrishnan, K. & Gandhi, V. Bcl-2 antagonists: a proof of concept for CLL therapy. Invest. New Drugs 31, 1384–1394 (2013).
Sperl, B., Seifert, M. H. & Berg, T. Natural product inhibitors of protein-protein interactions mediated by Src-family SH2 domains. Bioorg. Med. Chem. Lett. 19, 3305–3309 (2009).
Izumikawa, M. et al. JBIR-22, an inhibitor for protein-protein interaction of the homodimer of proteasome assembly factor 3. J. Nat. Prod. 73, 628–631 (2010).
Kaida, D. et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nature Chem. Biol. 3, 576–583 (2007).
Nakajima, H. et al. New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action. J. Antibiot. 49, 1204–1211 (1996).
Fan, L., Lagisetti, C., Edwards, C. C., Webb, T. R. & Potter, P. M. Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. ACS Chem. Biol. 6, 582–589 (2011).
Mousseau, G. et al. An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription. Cell Host Microbe 12, 97–108 (2012).
Carter, G. T. NP/MS since 1970: from the basement to the bench top. Nat. Prod. Rep. 31, 711–717 (2014). This review surveys the development of applications of mass spectrometric technologies in natural product research.
CHEMnetBASE. Dictionary of Natural Products (Taylor & Francis Group, 2013).
Sharma, V. & Sarkar, I. N. Leveraging biodiversity knowledge for potential phyto-therapeutic applications. J. Am. Med. Inform Assoc. 20, 668–679 (2013).
Akondi, K. B. & Lakshmi, V. V. Emerging trends in genomic approaches for microbial bioprospecting. OMICS 17, 61–70 (2013).
Martins, A., Vieira, H., Gaspar, H. & Santos, S. Marketed marine natural products in the pharmaceutical and cosmeceutical industries: tips for success. Mar. Drugs 12, 1066–1101 (2014).
Bai, R., Pettit, G. R. & Hamel, E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem. Pharmacol. 39, 1941–1949 (1990).
Bai, R. L. et al. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J. Biol. Chem. 266, 15882–15889 (1991).
McBride, A. & Butler, S. K. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer. Am. J. Health Syst. Pharm. 69, 745–755 (2012).
Yu, M. J., Zheng, W. & Seletsky, B. M. From micrograms to grams: scale-up synthesis of eribulin mesylate. Nat. Prod. Rep. 30, 1158–1164 (2013).
van Kesteren, C. et al. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin. Anticancer Drugs 14, 487–502 (2003).
Burns, L. H., Jin, Z. & Bowersox, S. S. The neuroprotective effects of intrathecal administration of the selective N-type calcium channel blocker ziconotide in a rat model of spinal ischemia. J. Vasc. Surg. 30, 334–343 (1999).
Cragg, G. M., Katz, F., Newman, D. J. & Rosenthal, J. The impact of the United Nations Convention on Biological Diversity on natural products research. Nat. Prod. Rep. 29, 1407–1423 (2012).
Krause, J. & Tobin, G. in Using Old Solutions to New Problems — Natural Drug Discovery in the 21st Century Ch. 1 (ed. Kulka, M.) (InTech, 2013).
Lallier, L. E. et al. Access to and use of marine genetic resources: understanding the legal framework. Nat. Prod. Rep. 31, 612–616 (2014). This informative paper presents an update on the legal landscape on global access and the benefit-sharing framework under the Nagoya Protocol and the United Nations Convention on the Law of the Sea.
Molinski, T. F. Microscale methodology for structure elucidation of natural products. Curr. Opin. Biotechnol. 21, 819–826 (2010). This review describes structural elucidation at microscale levels with microprobe NMR spectroscopy.
Molinski, T. F. NMR of natural products at the 'nanomole-scale'. Nat. Prod. Rep. 27, 321–329 (2010).
Dalisay, D. S. & Molinski, T. F. Structure elucidation at the nanomole scale. 3. Phorbasides G-I from Phorbas sp. J. Nat. Prod. 73, 679–682 (2010).
Williams, R. B. et al. Acetylated dammarane-type bisdesmosides from Combretum inflatum. J. Nat. Prod. 76, 1592–1597 (2013).
Williams, R. B. et al. Cytotoxic and antibacterial beilschmiedic acids from a Gabonese species of Beilschmiedia. J. Nat. Prod. 75, 1319–1325 (2012).
Starks, C. M. et al. Phenylpropanoids from Phragmipedium calurum and their antiproliferative activity. Phytochemistry 82, 172–175 (2012).
Williams, R. B. et al. Isolation of apoptosis-inducing stilbenoids from four members of the Orchidaceae family. Planta Med. 78, 160–165 (2012).
Gökay, O. & Albert, K. From single to multiple microcoil flow probe NMR and related capillary techniques: a review. Anal. Bioanal. Chem. 402, 647–669 (2012).
Smith, S. G. & Goodman, J. M. Assigning stereochemistry to single diastereoisomers by GIAO NMR calculation: the DP4 probability. J. Am. Chem. Soc. 132, 12946–12959 (2010).
Barone, G. et al. Structure validation of natural products by quantum-mechanical GIAO calculations of 13C NMR chemical shifts. Chemistry 8, 3233–3239 (2002).
Barone, G. et al. Determination of the relative stereochemistry of flexible organic compounds by ab initio methods: conformational analysis and Boltzmann-averaged GIAO 13C NMR chemical shifts. Chemistry 8, 3240–3245 (2002).
Irwin, J. J., Sterling, T., Mysinger, M. M., Bolstad, E. S. & Coleman, R. G. ZINC: a free tool to discover chemistry for biology. J. Chem. Inform. Model. 52, 1757–1768 (2012).
Laufer, R. S. & Dmitrienko, G. I. Diazo group electrophilicity in kinamycins and lomaiviticin A: potential insights into the molecular mechanism of antibacterial and antitumor activity. J. Am. Chem. Soc. 124, 1854–1855 (2002).
Holmes, T. C. et al. Molecular insights into the biosynthesis of guadinomine: a type III secretion system inhibitor. J. Am. Chem. Soc. 134, 17797–17806 (2012).
Gu, J. et al. Use of natural products as chemical library for drug discovery and network pharmacology. PLoS ONE 8, e62839 (2013).
Petersen, R. K. et al. Pharmacophore-driven identification of PPARgamma agonists from natural sources. J. Comp. Aided Mol. Des. 25, 107–116 (2011).
Chang, K. W. et al. iSMART: an integrated cloud computing web server for traditional Chinese medicine for online virtual screening, de novo evolution and drug design. J. Biomol. Struct. Dyn. 29, 243–250 (2011).
Tsai, T. Y., Chang, K. W. & Chen, C. Y. iScreen: world's first cloud-computing web server for virtual screening and de novo drug design based on TCM database@Taiwan. J. Comp. Aided Mol. Des. 25, 525–531 (2011).
Schuster, D. et al. Applications of integrated data mining methods to exploring natural product space for acetylcholinesterase inhibitors. Comb. Chem. High Throughput Screen. 13, 54–66 (2010).
Ntie-Kang, F. et al. AfroDb: a select highly potent and diverse natural product library from African medicinal plants. PLoS ONE 8, e78085 (2013).
Valli, M. et al. Development of a natural products database from the biodiversity of Brazil. J. Nat. Prod. 76, 439–444 (2013).
Ling, L. L. et al. A new antibiotic kills pathogens without detectable resistance. Nature. http://dx.doi.org/10.1038/nature14098 (2015).
The authors declare no competing financial interests.
- Chemical space
The multidimensional space occupied by all chemical compounds.
Molecules with atoms or chemical groups in a spatial arrangement known or predicted to be responsible for specific biological activity.
The spatial arrangement of atoms in a molecule.
The systematic, qualitative and quantitative analysis of all metabolites contained or produced in an organism at a specific time and under specific conditions.
The sequencing and analysis of DNA from environmental samples without the need for culturing individual clonal organisms.
Sharing certain characteristics — such as size, shape and solubility in water and organic solvents — with other molecules that act as drugs.
Logarithm of the octanol–water partition coefficient, which is a measure of a drug's lipophilicity. Defined as the ratio of un-ionized drug distributed between the octanol and water phases at equilibrium. Higher values imply greater lipophilicity.
- Rule of five
A set of criteria, known collectively as Lipinski's 'rule of five', that identify several key properties that should be considered for compounds with oral delivery in mind. These properties are as follows: molecular mass < 500 Da, cLogP < 5, number of hydrogen-bond donors < 5 and number of hydrogen-bond acceptors < 10.
The process of using spectroscopic methods to identify known metabolites during the preliminary screening stage and eliminating further isolation work on already well-studied natural products.
- One strain, many compounds
(OSMaC) An approach to activate metabolic pathways — by altering cultivation parameters, through co-cultivation or through the use of enzyme inhibitors or elicitors — that can be combined with genomics scanning.
- Cryptic gene clusters
Genes that are normally not expressed (are 'silent') and do not translate into a phenotypic difference but that can become visible in a different environment to generate phenotypic diversity.
About this article
Cite this article
Harvey, A., Edrada-Ebel, R. & Quinn, R. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov 14, 111–129 (2015). https://doi.org/10.1038/nrd4510
BMC Bioinformatics (2021)
Chinese Medicine (2021)
Acute, sub-acute, sub-chronic and chronic toxicity studies of four important Nigerian ethnomedicinal plants in rats
Clinical Phytoscience (2021)
Multiple copies of the oxytetracycline gene cluster in selected Streptomyces rimosus strains can provide significantly increased titers
Microbial Cell Factories (2021)
Nature Communications (2021)